Curcumin Targets EP300-Driven Glycolysis to Suppress Oral Cancer Growth (Scientific Reports, 2026)

Curcumin's reputation as an anticancer compound has long rested on a broad but sometimes vague body of evidence. A 2026 study in Scientific Reports sharpens that picture considerably for oral cancer, pinpointing a precise epigenetic mechanism: curcumin downregulates the enzyme EP300 and, through it, shuts down the glycolytic metabolism that oral squamous cell carcinoma depends on. This brief unpacks how the mechanism works, why the experimental design is convincing, and where the practical limits still lie.

Study Overview: What Was Investigated

A 2026 study published in Scientific Reports (DOI: 10.1038/s41598-026-44496-3) set out to answer a specific mechanistic question: how does curcumin — the principal active compound in turmeric — suppress the growth of oral squamous cell carcinoma (OSCC)? Prior research had established that curcumin has anticancer activity in many tumor types, but the precise molecular route in oral cancer was incompletely mapped. This study identified a concrete epigenetic mechanism, giving the "curcumin fights cancer" narrative a testable, molecular backbone.

OSCC is the most common malignancy of the oral cavity and is often aggressive, so understanding actionable molecular vulnerabilities is clinically meaningful. The researchers worked with established OSCC cell lines — UM-SCC-1 and HSC-3 — which allowed them to manipulate specific genes and observe the downstream consequences for cancer-cell metabolism and behavior.

The EP300-Glycolysis Axis: A New Target for Curcumin

The central finding centers on a protein called EP300, a histone acetyltransferase. Enzymes of this class modify chromatin — the packaging of DNA — and thereby regulate which genes are switched on. EP300 is overexpressed in OSCC, and the study links this overexpression to activation of the Warburg effect, the glycolytic metabolism that fuels rapid cancer growth.

The key result is that curcumin downregulates EP300 expression. By reducing EP300, curcumin dampens the epigenetic program that drives the cancer cell's glycolytic engine. Crucially, the researchers tested causality: when they forced EP300 overexpression, it partially reversed curcumin's inhibitory effect. This rescue experiment is the analytical heart of the paper — it demonstrates that EP300 is not merely correlated with the response but is a functional target through which curcumin acts. That level of mechanistic confirmation is what elevates a finding from "associated with" to "responsible for."

Downstream Glycolytic Targets: PKM2, LDHA, and GLUT1

Reducing EP300 does not act in a vacuum; it ripples downstream to the machinery of glycolysis itself. The study reported that curcumin's suppression of EP300 led to reduced activity or expression of three well-known glycolytic players:

• PKM2 (pyruvate kinase M2) — a glycolytic enzyme that cancer cells favor to support biosynthesis and rapid growth.
• LDHA (lactate dehydrogenase A) — converts pyruvate to lactate, a hallmark of Warburg metabolism.
• GLUT1 (glucose transporter 1) — the gateway that pulls glucose into the cell to feed glycolysis.

The functional consequence measured in the OSCC cell lines was a reduction in glucose uptake and lactate production — direct metabolic readouts confirming that the glycolytic pathway was genuinely being throttled. In other words, curcumin appears to starve the oral cancer cell of the metabolic advantage it relies on, by acting at an upstream epigenetic control point (EP300) that governs the whole downstream cascade.

Cellular Effects: Proliferation, Migration, Clonogenicity

Metabolic changes are only meaningful if they translate into altered cancer-cell behavior, and the study documented exactly that. Following curcumin treatment, the OSCC cells showed decreased proliferation (slower growth), reduced clonogenic capacity (a diminished ability to form colonies, which reflects the self-renewal potential linked to tumor initiation and recurrence), and impaired migration (reduced movement, a proxy for invasive and metastatic potential).

Together, these phenotypes paint a coherent picture: by disrupting the EP300–glycolysis axis, curcumin does not merely slow metabolism in the abstract — it undercuts the growth, self-renewal, and spread that make OSCC dangerous. Because these are the very properties oncologists care most about, the mechanism is biologically satisfying and points toward rational combination strategies in future research.

Clinical Implications and Bioavailability Challenge

The obvious enthusiasm this generates must be tempered by curcumin's oldest and most stubborn problem: poor bioavailability. Natural curcumin is poorly absorbed, rapidly metabolized, and quickly eliminated, so the concentrations that produce these effects in a dish are difficult to achieve in human tissue through ordinary oral intake. This is why much current research focuses on nanoformulations and synthetic curcumin analogues engineered to reach and sustain meaningful tissue levels. Formulations pairing curcumin with piperine (black pepper extract) are one common strategy to improve absorption.

This OSCC study also does not stand alone. It adds to a growing 2026 body of work on curcumin's energy-disrupting effects in cancer — most notably the January 2026 Wrocław University study (IJMS, DOI: 10.3390/ijms27115025), which reported that curcumin cut ATP production in fibrosarcoma cells by up to 92% and drove a large fraction into permanent senescence. Seen together, two mechanistically distinct 2026 studies — one on ATP depletion, one on EP300-driven glycolysis — describe a consistent theme: curcumin attacks the energy metabolism of cancer cells. That convergence strengthens the scientific rationale, even as the bioavailability gap and the absence of large human trials keep curcumin firmly in the "promising and investigational" category rather than the "proven therapy" one.

Frequently Asked Questions

Shop Sanare Lab

Lab-tested products referenced in the research above. Links are provided for convenience — always review the label and consult a professional before use.

Disclaimer: Links are informational and for convenience. This site does not provide medical advice and does not endorse any specific vendor. Always verify product quality, labeling, and consult a licensed professional for health decisions.

References

1. Curcumin suppresses OSCC by downregulating EP300-driven glycolysis. Scientific Reports, 2026. DOI: 10.1038/s41598-026-44496-3. Link
2. Curcumin-induced ATP depletion and senescence in fibrosarcoma cells. International Journal of Molecular Sciences (IJMS), January 2026. DOI: 10.3390/ijms27115025. Link

Medical Disclaimer

This article is for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.